ALPS GROUP INC (ALPS) Stock Fundamental Analysis

USA Nasdaq NASDAQ:ALPS • KYG0231P1081

0.94 USD
+0 (+0.46%)
Last: Feb 11, 2026, 01:32 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALPS. ALPS was compared to 523 industry peers in the Biotechnology industry. Both the profitability and financial health of ALPS have multiple concerns. ALPS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ALPS had negative earnings in the past year.
  • In multiple years ALPS reported negative net income over the last 5 years.
  • ALPS had a negative operating cash flow in each of the past 5 years.
ALPS Yearly Net Income VS EBIT VS OCF VS FCFALPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M -2M

1.2 Ratios

  • ALPS has a better Return On Assets (-25.77%) than 70.75% of its industry peers.
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROIC N/A
ROA(3y)-7.23%
ROA(5y)-18.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALPS Yearly ROA, ROE, ROICALPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPS Yearly Profit, Operating, Gross MarginsALPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

1

2. Health

2.1 Basic Checks

  • ALPS has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ALPS has been reduced compared to 5 years ago.
  • ALPS has a worse debt/assets ratio than last year.
ALPS Yearly Shares OutstandingALPS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALPS Yearly Total Debt VS Total AssetsALPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • ALPS has an Altman-Z score of -2.11. This is a bad value and indicates that ALPS is not financially healthy and even has some risk of bankruptcy.
  • ALPS has a Altman-Z score (-2.11) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.11
ROIC/WACCN/A
WACCN/A
ALPS Yearly LT Debt VS Equity VS FCFALPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • ALPS has a Current Ratio of 0.25. This is a bad value and indicates that ALPS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ALPS's Current ratio of 0.25 is on the low side compared to the rest of the industry. ALPS is outperformed by 92.16% of its industry peers.
  • A Quick Ratio of 0.25 indicates that ALPS may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.25, ALPS is not doing good in the industry: 91.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
ALPS Yearly Current Assets VS Current LiabilitesALPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

0

3. Growth

3.1 Past

  • ALPS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -216.17%.
EPS 1Y (TTM)-216.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALPS Yearly Revenue VS EstimatesALPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 20K 40K 60K 80K 100K

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALPS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPS Price Earnings VS Forward Price EarningsALPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPS Per share dataALPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for ALPS!.
Industry RankSector Rank
Dividend Yield 0%

ALPS GROUP INC

NASDAQ:ALPS (2/11/2026, 1:32:44 PM)

0.94

+0 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners56.7%
Ins Owner Change0%
Market Cap156.42M
Revenue(TTM)N/A
Net Income(TTM)-978.50K
AnalystsN/A
Price TargetN/A
Short Float %0.19%
Short Ratio0.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.23%
ROA(5y)-18.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -2.11
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-216.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-45.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.4%
OCF growth 3YN/A
OCF growth 5YN/A

ALPS GROUP INC / ALPS FAQ

What is the fundamental rating for ALPS stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALPS.


What is the valuation status of ALPS GROUP INC (ALPS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ALPS GROUP INC (ALPS). This can be considered as Overvalued.


How profitable is ALPS GROUP INC (ALPS) stock?

ALPS GROUP INC (ALPS) has a profitability rating of 1 / 10.


What is the financial health of ALPS GROUP INC (ALPS) stock?

The financial health rating of ALPS GROUP INC (ALPS) is 1 / 10.


Can you provide the dividend sustainability for ALPS stock?

The dividend rating of ALPS GROUP INC (ALPS) is 0 / 10 and the dividend payout ratio is 0%.